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In this study, the optimisation of biopharmaceutical properties of a dried commercial extract of St John’s Wort
were evaluated employing the in vivo forced swimming test (FST). Three new dosage forms containing β-
cyclodextrin and surfactants (SDS, ASC8) were compared in the FST with the commercial extract. The
commercial extract showed antidepressant activity in mice after 60 min at a dosage of 100 mg/kg. The same
antidepressant activity appeared in 30 min with a micellar solution of SDS containing the same quantity of
extract (100 mg/kg), while with micelles of ASC8 the effect appeared at 15 min and with a dosage of 30 mg/
kg. In the case of β-cyclodextrin the best results were obtained at 30 min, administering 60 mg/kg of the
extract. Finally, the influence of the formulations on the water solubility of the constituents of the extract is
reported. The tensides dramatically enhanced solubility, in particular that of the more lipophilic compounds,
in the case of β-cyclodextrin this effect was very pronounced for flavonoids and biapigenin, lower for hypericins
and practically insignificant for hyperforins. Copyright © 2008 John Wiley & Sons, Ltd.
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is very scarce; phloroglucinols are highly lipophilic
constituents. The bioavailability of the extract’s active
principles is very low, as shown by some studies re-
ported in the literature (Kubin et al., 2005; Schulz et al.,
2005; Wurglics and Schubert-Zsilavecz, 2006) and the
maximum plasma levels were reached after a lag time
of 3– 6 h depending on the constituents (Biber et al.,
1998; Agrosì et al., 2000). To our knowledge, a single
report appears concerning an alternative formulation
to the widely diffused tablets or hard capsules of the
dried extracts; it is represented by the soft gelatin cap-
sule technology containing inter alia the dried extract
and soya oil. This new dosage form exhibited a higher
individual absorption of both hyperforin and hypericin
when compared with the corresponding data for hard
gelatin capsules of the dried extract (Agrosì et al., 2000).
In the present study the effect of SDS and ASC8
surfactants and β-cyclodextrin on the biopharmaceu-
tical properties of SJW extract were evaluated. A phar-
macological approach, instead of the pharmacokinetic
one, was used in order to evaluate the improvement
of the properties of the new developed formulations.
The mouse forced swimming test (Porsolt test, FST)
(Porsolt et al., 1977) – a behavioural model where anti-
depressant drugs clomipramine and amitriptyline are
active – was used to test the antidepressant-like activity of
the different dosage forms and the data were compared
with those obtained with the widely used dried extract.
The aim of this work was to develop new oral formu-
lations with a better pharmacokinetic, a more rapid
onset and prolonged action with respect to the extract
alone and to verify the possibility of reducing the dosage
of total extract while obtaining the same antidepressant-
like effect with minor potential side-effects. Finally,
the influence of β-cyclodextrin and micelles on the
INTRODUCTION
The World Health Organization ranks depression as
fourth among the world’s greatest health problems,
with psychiatric pain most often diagnosed (Chatterjee
et al., 1998a,b).
Hypericum perforatum L. (St John’s Wort, SJW)
has been used since antiquity mainly for external
use, but the quantified extract has become increasingly
popular in the last ten years in Europe and the USA
for the treatment of mood disorders, especially con-
ditions of mild to moderate depression according to
ICD-10 (ESCOP 1997; Harrer et al., 1994; Rasmussen,
1998).
Generally, the herbal medicinal products are formu-
lated from the quantified extracts which contain a variety
of compounds including a broad range of flavonols, based
on quercetin aglycone; naphthodianthrones (hypericin
and pseudohypericin) and phloroglucinol derivatives
such as hyperforin, adhyperforin and others. In the lit-
erature, many papers demonstrate the synergic effects
between different constituents of Hypericum perforatum
L. (Butterweck et al., 1998; Noldner and Schotz, 2002;
Butterweck, 2003). All the constituents of the extract
are considered active markers and, in general, the
effects of these preparations are assumed to arise from
the whole mixture of these main constituents (Gaedcke
and Steinhoff, 2003; Council of Europe, 2005).
Thus, flavonols and naphtodiantrones are polyphenols
and quite polar derivatives but their water solubility
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solubility of the constituents of the extract within the
formulations was evaluated to better elucidate the re-
sults obtained from the pharmacological tests.
MATERIALS AND METHODS
Materials. Acetonitrile and MeOH (HPLC grade) were
purchased from Merck (Darmstadt, Germany); 85%
formic acid was provided by Carlo Erba (Milan, Italy).
Water was purified by a Milli-Qplus system from Millipore
(Milford, MA, USA).
Indena Research Laboratories (Settala, Milan, Italy)
offered a commercial sample of Hypericum perforatum
L. dried extract – Lotto 28662/M1 – B.A. 84204 and
kindly provided the reference rutin trihydrate (Batch
no. K12408717, standard purity 96.25% considering
the content of residual solvents, moisture and amount
of impurities).
KLEPTOSE® β-cyclodextrin (Roquette Frères, S.A.
Lestrem, France); sodium dodecyl sulfate (SDS) (Sigma
Chemical Co., St. Louis, USA); ottanoic acid 98+%
(Aldrich, Steinheim, Germany); and L-ascorbic acid 99%
(Aldrich, Steinheim, Germany). Octanoyl-6-O-ascorbic
acid (ASC8) was synthesised according to the procedure
reported in literature (Capuzzi et al., 1996); water con-
tent and purity were checked by elemental analysis
(theoretical C 55.62%, H 7.33%; found C 53.80%, H
7.45%). Ethanol was analytical reagent grade from Riedel-
de Haen (Seelze, Germany). Carboxymethylcellulose
Sodium Salt, (CMC) (Fluka Chemie GmbH, Steinheim,
Germany); clomipramine hydrochloride, amitriptyline
hydrochloride (Sigma, Milan, Italy); and amphetamine
(St Louis, MO, USA).
Animals. Male Swiss albino mice (23–25 g) from the
Morini (San Polo d’Enza, Italy) breeding farm were
used. Fifteen mice were housed per cage (26 × 41 cm).
The cages were placed in the experimental room 24 h
before the test for acclimatization. The animals were
fed a standard laboratory diet and tap water ad libitum
and kept at 23 ± 1 °C with a 12-h light/dark cycle, light
on at 7 a.m. Animals were naïve and used only once. All
experiments were carried out in accordance with the
Animal Protection Law of the Republic of Italy, DL n.
116/1992, based on the European Community’s Council
Directive of 24 November 1986 (86/609/EEC).
HPLC-DAD and HPLC-MS drug analyses. To evaluate
the constituents’ content, an HPLC analysis was performed
using a method described in the literature (Bergonzi
et al., 2001). Identification of the constituents was per-
formed using combined HPLC-diode array detection
(DAD) analysis and HPLC-thermospray mass spectro-
metry. Quantification of the constituents was performed
using rutin as an external standard and considering each
constituent and the relative response factor (RRF) with
respect to rutin, as previously reported (Brolis et al.,
1998).
All the samples were analysed in triplicate and a
calibration graph with six data points of external stand-
ard was used. The content of each constituent of the
drug substance is reported in Table 1.
The HPLC system consisted of a HP 1100 L instrument
with a diode array detector managed by a HP 9000
Table 1. Dried extract composition (mg/100mg)
Constituent Content % (mg/100 mg), ±S.D.
Rutin 4.28 ± 1.23
Hyperoside 6.35 ± 1.02
Isoquercitrin 0.61 ± 0.08
Quercitrin 0.65 ± 0.08
Quercetin 0.83 ± 0.13
I3,II8-Biapigenin 0.62 ± 0.08
Total flavonols 12.72 ± 1.08
Total hyperforins 4.23 ± 0.01
Total hypericins 0.32 ± 0.03
workstation (Agilent Technology, Palo Alto, CA, USA).
The reverse-phase column was a 201 TP 54 (250 × 4.6 mm,
6 mm, 5 μm, Vydac Separation Group, Hesperia, CA,
USA) maintained at 26 °C. The mobile phase was a
linear solvent gradient CH3CN/CH3OH/H2O (pH 3.2,
HCOOH) over a 60-min period at a flow rate of 1 ml/
min, as previously reported (Bergonzi et al., 2001).
Before the HPLC analysis, each sample was filtered
through a cartridge-type sample filtration unit with a
polytetrafluoroethylene (PTFE) membrane (d = 13 mm,
porosity 0.45 μm, Lida manufacturing Corp.) and
immediately injected. The injected volume of sample
was a 25-μl solution. UV–Vis spectra were recorded
in the range 200–590 nm, and chromatograms were
acquired at 230, 254, 270, 350 and 590 nm.
The HPLC system was interfaced with a HP 1100 MSD
API-electrospray (Agilent Technology, Palo Alto, CA,
USA). The interface geometry, with an orthogonal
position of the nebulizer with respect to the capillary
inlet, allowed the use of analytical conditions similar to
those of the HPLC-DAD analysis. The same column,
mobile phase, time period and flow rate were used. Mass
spectrometry operating conditions were optimized in
order to achieve maximum sensitivity values; gas tem-
perature 350 °C at a flow rate of 10 l/min, nebulizer
pressure 30 p.s.i., quadrupole temperature 30 °C, and
capillary voltage 3500 V. Full scan spectra from m /z
100–800 in the positive ion mode were obtained (scan
time 1 s).
Forced swimming test (FST). The FST used was the same
as described by Porsolt (Porsot et al., 1977). Briefly,
mice were dropped individually into glass cylinders
(height: 25 cm, diameter: 10 cm) containing 6 cm of
water maintained at 22–23 °C and left there for 6 min.
A mouse was judged to be immobile when it floated
in the water, in an upright position, and made only small
movements to keep its head above water. The duration
of immobility was recorded during the last 4 min of the
6-min test. A decrease in the duration of immobility is
indicative of an antidepressant-like effect. Twenty-four
mice per group were tested. The experiments reported
in each figure were performed on the same day. Each
treated group was compared to the corresponding control
group. The observers were unaware of the treatments.
The experiments were performed blind. To evaluate
the antidepressant-like activity of a compound in the
FST not only a dose-response but also a time-course study
must be performed in order to determine the most
appropriate administration schedule. The reference
drugs were tested concomitantly with the unformulated
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extract. Time-course experiments performed in our
laboratory indicated that the amitriptyline maximum
antidepressant-like effect was reached 30 min after
administration (data not shown); amitriptyline 10 mg/
Kg s.c. reduced time immobility to 102.5 ± 10.4 (P < 0.001);
clomipramine 25 mg/Kg s.c. reduced time immobility to
139.1 ± 12.3 (P < 0.001).
Hole-board test. The hole-board test consisted of a
40-cm square plane with 16 flush-mounted cylindrical
holes (3 cm diameter) distributed four by four in an
equidistant, grid-like manner. Mice were placed on the
centre of the board one by one and allowed to move
about freely for a period of 5 min each. Two electric
eyes, crossing the plane from mid-point to mid-point
of opposite sides, thus dividing the plane into equal
quadrants, automatically signalled the movement of
the animal (counts in 5 min) on the surface of the plane
(locomotor activity). Miniature photoelectric cells,
in each of the 16 holes, recorded (counts in 5 min)
the exploration of the holes (exploratory activity)
by the mice. Twenty-four mice per group were tested.
Amphetamine was used as reference drug.
Rota-rod test. The apparatus consisted of a base plat-
form and a rotating rod with a diameter of 3 cm and
a non-slippery surface. The rod was placed at a height
of 15 cm from the base. The rod, 30 cm in length, was
divided into five equal sections by six disks. Thus, up to
five mice were tested simultaneously on the apparatus,
with a rod-rotating speed of 16 rpm. The integrity of
motor coordination was assessed on the basis of the
number of falls from the rod in 30 s according to Vaught
(1985). Those mice scoring more than six falls in the
pre-test were rejected (20%). The performance time
was measured before (pre-test) and 15, 30 and 45 min
after the beginning of the test. Twenty-four mice per
group were tested.
Drugs. Clomipramine and amitriptyline were dissolved
in water solution immediately before use. Drug con-
centrations were prepared so that the necessary dose
could be administered in a volume of 10 ml kg−1. Doses
and administration schedule were chosen on the basis
of time-course and dose–response experiments previ-
ously performed in our laboratory. Furthermore, lit-
erature data confirm the selectivity and efficacy of the
above mentioned treatments at the times and concen-
trations used.
SJW dried commercial extract was dissolved in a 1%
CMC solution immediately before use and administered
by gavage. Different extract concentrations from 10 to
1000 mg kg−1 were tested.
New developed formulations. Aqueous formulations
of the SJW dried commercial extract (100 mg kg−1) were
prepared using ASC8 and SDS 40 mM solutions by
sonication for 15 min.
The β-cyclodextrin formulation (β-Cd/extract 2:1 w/w)
was prepared by colyophilized method (Hedges, 1998).
Solubility test. Solubility studies of the extracts were
carried out in water at 26 ± 0.5 °C. Saturated solutions
of Hypericum perforatum L. extract in water or in
micellar solution of SDS and ASC8 40 mM and a satu-
rated solution of colyophilized with β-Cd were prepared.
After 24 h, an aliquot of the four suspensions was
filtered (pore size 0.45 μm) and the constituents’ con-
centration was determined by HPLC-DAD-MS analy-
sis. Each experiment was performed in triplicate.
Statistical analysis. All experimental results are given
as the mean ± SEM. An analysis of variance ANOVA,
followed by Fisher’s Protected Least Significant Dif-
ference procedure for post hoc comparison, was used
to verify the significance between the two means of
behavioural results. Data were analyzed with the
StatView software for the Macintosh (1992). P values
of less than 0.05 were considered significant.
RESULTS
As a first step of our investigation, we evaluated the
dose of total extract to obtain a significant reduction
in time immobility. Dried commercial extract, dispersed
in a CMC 1% solution, showed an antidepressant-like
effect in the mice after 60 min with a dosage of 30, 60
and 100 mg/Kg administered orally (p.o.) which reduced
time immobility to 143.1 ± 10.3 (P < 0.01), 133.7 ± 14.6
(P < 0.01) and 142.4 ± 10.2 (P < 0.01) s respectively
(bell-trend). The doses of 10, 150, 300 and 1000 mg/kg
p.o. were devoid of any effect (Fig. 1).
A dose of 100 mg/Kg was chosen as reference for the
innovative forms because it gave the most reproducible
data (Fig. 1). The time-course of the commercial ex-
tract at a dosage of 100 mg/Kg p.o. showed a brief range
of activity, after only 60 min (immobility time = 136.4 ±
15.4 s., P < 0.001) (Fig. 2). The observed antidepres-
sant-like effect disappeared 90 min after administration.
The behaviour of three tested formulations, contain-
ing all the same quantity of extract corresponding to a
dosage of 100 mg/Kg was reported in Figs 3, 4 and 5.
A micellar solution of SDS showed an antidepres-
sant activity similar to that of the extract alone after
30 min (immobility time = 150.7 ± 8.2 sec., P < 0.05),
subsequently the effect disappeared (Fig. 3).
A micellar solution of ASC8 containing the same
quantity of extract corresponding to a dosage of 100 mg/
Kg reduced immobility time after 15 and 30 min to
136.4 ± 11.2 s (P < 0.05) and 129.6 ± 11.4 s, respectively
(P < 0.05) (Fig. 4).
Finally, we tested the preparation with β-cyclodextrin
in ratio by weight 1:2. With a dosage of 100 mg/Kg, the
antidepressant-like effect was obtained after 30 min,
reducing significantly immobility time to 130.9 ± 11.3 s
(P < 0.01); the effect remained also after 60 min
(immobility time = 128.9 ± 11.7 s, P < 0.01) (Fig. 5).
Then, we tested the same formulations with lower
content of extract, trying to reduce the dosage of the
Hypericum perforatum L. The more significant results
were reported in Figs 6 and 7, where we reported the
dose-response curve for antidepressant-like effect of
ASC8 and β-cyclodextrin formulations after 15 (A),
30 (B) and 60 (C) min after administration. The lower
dosage utilizable with a micellar solution of ASC8 was
30 mg/Kg. In this case the formulation resulted still
active and reduced immobility time after only 15 min
to 126.2 ± 11.3 s (P < 0.05) (Fig. 6A) and after 30 min
to 140.8 ± 14.1 s (P < 0.05) (Fig. 6B). The antidepressant-
like effect with β-cyclodextrin was obtained with a dosage
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Figure 1. Curve dose-response of different dosages of St. John’s wort commercial extract after 60 minutes.
Figure 2. Time course of St. John’s wort commercial extract
with at a dosage of 100 mg/Kg p.o. Figure 3. Time course of micellar solution of SDS 40 mM with
at a dosage of 100 mg/Kg p.o.
of 60 mg/Kg after 30 min (Fig. 7B) and it reduced sig-
nificantly immobility time to 151.3 ± 9.2 s (P < 0.01);
the effect remained also after 60 min (immobility time
= 145.4 ± 8.6 s, P < 0.01) (Fig. 7C).
However, drugs that increase motor activity may
produce false positives in the Porsolt’s test (Borsini
and Meli, 1988; Detke and Lucki, 1995) thus it was
necessary to conduct the hole-board test in parallel to
evidenced possible alterations of spontaneous motility
and explorative activity and the Rota-rod test to evalu-
ate the influence on motor coordination of the extract
and the other vehicles investigated.
No statistical differences were noted between controls
and mice pre-treated with the highest effective dose of
extract (100 mg/Kg), SDS, ASC8 and β-cyclodextrin.
The spontaneous motility as well as the exploratory
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Figure 4. Time course of micellar solution of ASC-8 40 mM with
at a dosage of 100 mg/Kg p.o.
animals treated with all substances in comparison with
the control group. During each session there would
have been a decrease in the number of falls if motor
coordination was not altered (Fig. 9).
The solubility of three main classes of compounds
of Hypericum perforatum L., flavonoids, hyperforins
and hypericins, was affected by the different excipients
of the formulations. The results obtained are reported
in Table 2.
Concerning the extract, water solubility at 26 °C was
353.66 μg/ml for flavonoids and 10.40 μg/ml for hypericins,
while that of hyperforins was ≅ 10−1 μg/ml.
The solubility of flavonoids in the presence of β-
cyclodextrin and SDS was increased three times and
with ASC8 six times. Also the solubility of biapigenin
increased in the formulations ranging from 6.87 μg/ml
to 150.34 μg/ml; the highest was obtained in the micellar
solution of ASC8.
The total amount of hypericins was 21.26 μg/ml in
the case of β-cyclodextrin, 44.31 μg/ml with SDS micelles
and 72.18 μg/ml with ASC8 micelles.
The most interesting results concern the phloroglu-
cinol solubilities. The water solubility and solubility in
the β-cyclodextrin formulation was ≅ 10−1 μg/ml. Micelles
had a high influence on hyperforins: their solubility was
15.85 μg/ml with SDS and 94.99 μg/ml with ASC8.
DISCUSSION
In this study oral dosage forms containing surfactants
(SDS, ASC8) and β-cyclodextrin were evaluated by
in vivo Porsolt’s test and the resulting data were
compared with those obtained with the extract alone.
Antidepressant-like activity was evaluated in the con-
ventional conditions of the FST; this is a good experi-
mental model where antidepressant drugs used in clinical
therapy showed their action reducing time immobility.
The decrease in the immobility time induced by the
extract was compared to that induced by the antidepres-
sant drug amitriptyline used as reference compound.
The micellar solution of SDS 40 mM showed a rapid
onset compared to the extract alone, but with this
anionic surfactant it was not possible reduce the dosage.
Better results were obtained with the micelles of
ASC8. In addition to behaving as a surfactant, with
a low CMC (8.1 mM), ASC8 retains the antioxidant
properties of vitamin C and acts as a powerful radical
scavenger both in aqueous and in non-aqueous media.
It is under consideration for human use, and may
be suitable both for oral and parenteral formulation.
The micelles of ASC 8 represent a valid formulation
to decrease the dosage active of the extract until 30 mg/
Kg, with a better pharmacokinetic profile.
Table 2. Solubility of constituents (μg/ml) of Hypericum perforatum L. extract in water and in three different dosage forms: β-Cd
colyophilized, SDS and ASC8 micelles.
Constituents H2O β-Cd SDS 40 mM ASC-8 40 mM
Flavonoids 353.66 ± 11.72 1172.77 ± 18.22 1021.39 ± 12.56 1841.02 ± 13.42
I3,II8-biapigenin 6.87 ± 0.27 59.68 ± 0.78 137.47 ± 1.42 150.34 ± 6.31
Total hyperforins ≅10−1 ≅10−1 15.85 ± 0.95 94.99 ± 3.93
Total hypericins 10.40 ± 0.30 21.26 ± 1.06 44.31 ± 3.00 72.18 ± 2.62
Figure 5. Time course of the colyophilized St. John’s wort at
100 mg/Kg:β-CD 1:2 w/w p.o.
activity of mice was unmodified by treatment with the
above-mentioned compounds in comparison with con-
trol groups (Fig. 8).
The number of falls from the rotating rod showed
a lack of any impairment in motor coordination of
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Figure 6. Dose-response curve for the antidepressant effect of ASC8 40 mM micelles of St. John’s wort commercial extract A: 15 min
after administration, B: 30 min after administration, C: 60 min after administration.
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Figure 7. Dose-response curve for the antidepressant effect of β-CD formulation of St. John’s wort commercial extract A: 15 min after
administration, B: 30 min after administration, C: 60 min after administration.
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The motility observed in the Porsolt’s test really
represented the measure of the antidepressant-like
effect and it was not to be considered a side-effect, as
evidenced by Rota-rod test and hole-board test. More-
over pharmacological modulators did not produce any
alteration in motor coordination, spontaneous motility
and exploratory activity at all doses tested (data not
shown). Neither alteration of animals’ gross behaviour
nor signs of toxicity/death of mice treated with all the
investigated compounds was observed up to seven days
following treatment (data not shown).
A second part of our work concerned the influence
of the dosage forms on the water solubility of the ex-
tract’s constituents. This parameter could be useful to
interpret the pharmacological behaviour of the extract
formulated with the technological excipients.
If we compare the results obtained within the phar-
macological assays with those obtained from the water
solubility studies, ASC8 micelles resulted the best
formulation for Hypericum perforatum L., decreasing
the active dosage and showing a better pharmacokinetic
profile. These results can be explained by a notable
influence of surfactant on the solubility of all the con-
stituents of the extract, particularly regarding hyperforin
solubility.
Also the formulation with β-cyclodextrin had a more
rapid onset in the Porsolt test, having a maximum of
peak of activity after 30 min. This excipient influences
Figure 8. Evaluation of the effect of St. John’s wort and other vehicles regarding spontaneous motility and explorative activity
through the hole board test.
Figure 9. Evaluation of the effect of vehicles (a) and vehicles with St. John’s wort (b) regarding motor coordination with the Rota rod
test.
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the solubility of flavonoids and hypericins, but not with
regards to hyperforins. In particular, for such com-
pounds it can act as an enhancer of penetration and
increases the abortion of all constituents, as reported
in the literature (Rajewski and Stella, 1996; Hirayama
and Uekama, 1999).
In summary, all these new oral formulations showed
in the Porsolt test a more rapid onset and prolonged
action as well as the possibility of reducing the dosage
of total extract of SJW to obtain the same antidepres-
sant-like effect with minor potential side-effects.
The extract alone demonstrated antidepressant acti-
vity in mice after 60 min with a dosage of 100 mg/Kg. A
similar antidepressant-like activity appeared in 30 min
with a micellar solution of SDS containing the same
quantity of extract (100 mg/Kg), while with micelles of
ASC8 the effect appeared after 15 min with a dosage of
30 mg/Kg. In the case of preparation with β-cyclodextrin,
the best results were obtained at 30 min administering
60 mg/Kg of the extract.
To interpret the pharmacological behaviour of the
extract formulated with the technological excipients,
the effect of the dosage forms on the water solubility of
the extract’s constituents was evaluated. If tensides
can dramatically enhance solubility, in particular that
of the more lipophilic compounds, in the case of β-
cyclodextrin this effect is very pronounced for flavonoids
and biapigenin, lower for hypericins and practically in-
significant for hyperforins. The pharmacological results
have pointed out the possibility of this excipient to
ameliorate drug availability through a facilitation of
the absorption.
